Provided by Tiger Fintech (Singapore) Pte. Ltd.

NeuroPace Inc.

10.41
-0.1900-1.79%
Volume:273.09K
Turnover:2.87M
Market Cap:341.43M
PE:-12.56
High:10.73
Open:10.60
Low:10.38
Close:10.60
Loading ...

Sector Update: Health Care Stocks Decline Late Afternoon

MT Newswires Live
·
15 Feb

BUZZ-Neuropace falls on discounted pricing of public offering

Reuters
·
14 Feb

Sector Update: Health Care Stocks Flat to Higher Premarket Friday

MT Newswires Live
·
14 Feb

BRIEF-NeuroPace Prices Public Offering Of 6.5 Million Shares At $10 Each

Reuters
·
14 Feb

NeuroPace Prices $65 Million Offering; Shares Drop in Pre-Market

GuruFocus.com
·
14 Feb

NeuroPace Prices $65 Million Public Offering

MT Newswires Live
·
14 Feb

Neuropace Announces Pricing of Public Offering of $65 Million of Common Stock

THOMSON REUTERS
·
14 Feb

Neuropace Inc - Prices Public Offering of 6.5 Mln Shares at $10.00 Each

THOMSON REUTERS
·
14 Feb

NeuroPace Plans $65 Million Public Offering; Shares Tumble After Hours

MT Newswires Live
·
14 Feb

BRIEF-Neuropace Announces Proposed Public Offering Of $65 Million Of Common Stock

Reuters
·
14 Feb

NeuroPace $65M Spot Secondary expected to price at $10

TIPRANKS
·
14 Feb

NeuroPace announces $65M common stock offering

TIPRANKS
·
14 Feb

Neuropace Announces Proposed Public Offering of $65 Million of Common Stock

THOMSON REUTERS
·
14 Feb

NeuroPace Announces Proposed Public Offering of $65 Million of Common Stock

GlobeNewswire
·
14 Feb

Neuropace Announces Upcoming Oral Presentation of Data From the Post-Approval Study of the Rns System at the American Academy of Neurology 2025 Annual Meeting Being Held April 5TH – 9TH

THOMSON REUTERS
·
04 Feb

NeuroPace Announces Upcoming Oral Presentation of Data from the Post-Approval Study of the RNS System at the American Academy of Neurology 2025 Annual Meeting Being Held April 5th – 9th

GlobeNewswire
·
04 Feb

NeuroPace Is Maintained at Overweight by Wells Fargo

Dow Jones
·
31 Jan

NeuroPace: Strategic Growth and Market Expansion Drive Positive Outlook

TIPRANKS
·
30 Jan

NeuroPace: Strong Growth Trajectory and Upcoming Catalysts Justify Buy Rating

TIPRANKS
·
30 Jan

Cantor Fitzgerald Sticks to Their Buy Rating for NeuroPace (NPCE)

TIPRANKS
·
29 Jan